Cancer reports最新文献

{"title":"Human Epidermal Growth Factor Receptor 2-Positive, Claudin-18 Isoform 2-Positive, Mismatch Repair-Deficient Gastric Cancer Revealed by Immunohistochemical Analysis of Surgical Specimens: A Case Report","authors":"Daichi Takagi,&nbsp;Mikito Mori,&nbsp;Kiyohiko Shuto,&nbsp;Chihiro Kosugi,&nbsp;Akihiro Usui,&nbsp;Ryosuke Takayanagi,&nbsp;Shunsuke Sato,&nbsp;Sumiyo Adachi,&nbsp;Takashi Fujino,&nbsp;Kazuto Yamazaki,&nbsp;Hiroaki Shimizu","doi":"10.1002/cnr2.70646","DOIUrl":"10.1002/cnr2.70646","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) proteins, claudin-18 isoform 2 (CLDN18.2), and the programmed cell death ligand-1 combined positive score (PD-L1 CPS) are predictive biomarkers for the efficacy of combination chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer. However, only a small proportion of these patients are positive for at least two of these predictive biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We present a rare case of HER2-positive, CLDN18.2-positive, MMR-deficient gastric cancer. A 72-year-old man was initially diagnosed with clinical stage IVB gastric cancer (cT4aN0, M1 PUL). Immunohistochemical analysis of endoscopic biopsy specimens revealed HER2-negative, CLDN18.2-negative, and MMR-proficient gastric cancer. He underwent surgery to remove the hemorrhagic gastric cancer before chemotherapy, and immunohistochemical analysis of surgical specimens revealed HER2-positive, CLDN18.2-positive, and MMR-deficient gastric cancer. Moreover, a transbronchial lung biopsy after surgery showed that one of the bilateral multiple lung nodules was lung adenocarcinoma, and he was ultimately diagnosed with pathological stage IIB gastric cancer and clinical stage IVB lung cancer. He died of lung cancer without any signs of gastric cancer recurrence during 17 months of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HER2-positive, CLDN18.2-positive, MMR-deficient gastric cancer is extremely rare. Adequate endoscopic biopsy sampling from different areas of a tumor is essential for accurate predictive biomarker assessment in patients with gastric or gastroesophageal junction cancer because of intratumoral heterogeneity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13447005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma","authors":"Ali Nakhaei,&nbsp;Atefeh Taghavi,&nbsp;Amir R. Afshari,&nbsp;Farzaneh Davoudi,&nbsp;Elaheh Gheybi,&nbsp;Mohammad Jalili-Nik","doi":"10.1002/cnr2.70643","DOIUrl":"10.1002/cnr2.70643","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT-dependent DNA repair and activation of pro-survival pathways, could decrease treatment efficacy. Drug repurposing offers an attractive strategy to identify agents that may enhance TMZ activity because these drugs already have known pharmacokinetic and safety profiles. This narrative review summarizes the available evidence on repurposed drugs investigated as potential modulators of TMZ response in GB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>A range of repurposed agents, including chloroquine, valproic acid, levetiracetam, metformin, aspirin, amlodipine, atorvastatin, chlorpromazine, melatonin, disulfiram, bortezomib, and verteporfin, have been evaluated in GB models and selected clinical studies. Reported mechanisms include modulation of MGMT expression, autophagy, oxidative stress, apoptosis, DNA-damage responses, cancer stem-cell properties, and signaling pathways such as PI3K/AKT/mTOR, AMPK, EGFR, STAT3, ERK1/2, and NF-κB. Several agents have enhanced TMZ-associated cytotoxicity in cell culture and animal models. However, clinical evidence remains limited, and the results are inconsistent for some drugs. Blood–brain barrier penetration, achievable intratumoral drug exposure, toxicity, treatment scheduling, and molecular heterogeneity of GB remain major translational challenges.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Repurposed drugs may provide useful candidates for improving TMZ-based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood–brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well-designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Carcinoma Cuniculatum: Diagnostic Challenges and Emerging Perspectives—Case Report","authors":"Toniya Raut,&nbsp;Neetu Jain,&nbsp;Shashi Keshwar,&nbsp;Ashok Dongol,&nbsp;Mehul Rajesh Jaisani,&nbsp;Yamuna Agrawal,&nbsp;Mona Dahal","doi":"10.1002/cnr2.70644","DOIUrl":"10.1002/cnr2.70644","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oral carcinoma cuniculatum (OCC) is a rare subtype of squamous cell carcinoma (SCC). It is characterized by a locally aggressive, burrowing lesion associated with an osteolytic defect yet lacks obvious cytological atypia. Although OCC has been described in the literature, its rarity, clinical unfamiliarity, and distinct burrowing pattern frequently result in misdiagnosis or underdiagnosis during incisional biopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Description</h3>\u0000 \u0000 <p>This report describes a case of OCC arising on the residual alveolar ridge of a 71-year-old male. Microscopic similarities between conventional SCC and verrucous carcinoma obscure the subtle yet pathognomonic features of OCC. Notably, this case also demonstrates perineural invasion, a finding rarely associated with OCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Oral carcinoma cuniculatum remains underexplored and overlooked. This report aims to contribute to the scientific literature by emphasizing diagnostic procedure, highlighting the rarity, and deceptive clinical and histopathological features of OCC. It underscores the importance of considering OCC in the differential diagnosis when repeated incisional biopsies fail to confirm malignancy in a clinically suspicious lesion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of Metabolic Hub Genes Using WGCNA and Prognostic Risk Modeling in Acute Myeloid Leukemia","authors":"Samaneh Ramezani,&nbsp;Fatemeh Akhoundi,&nbsp;Reza Valadan,&nbsp;Hossein Asgarian-Omran","doi":"10.1002/cnr2.70645","DOIUrl":"10.1002/cnr2.70645","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute myeloid leukemia (AML) is an aggressive and molecularly heterogeneous hematologic malignancy associated with poor clinical outcomes, particularly in elderly and high-risk patients. Increasing evidence suggests that metabolic reprogramming plays a critical role in leukemia progression, immune dysregulation, and therapeutic resistance. However, the prognostic value of metabolism-associated molecular networks in AML remains insufficiently understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to identify metabolism-related hub genes involved in AML progression and to establish a robust prognostic signature for survival prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Integrated transcriptomic analyses were performed using multiple Gene Expression Omnibus datasets and the TCGA-LAML cohort. Weighted gene co-expression network analysis identified AML-associated gene modules, followed by protein–protein interaction and functional enrichment analyses. Metabolic-related hub genes were selected through integration with curated metabolic gene sets. A prognostic model was subsequently developed using univariable and least absolute shrinkage and selection operator (LASSO) Cox regression analyses and validated in independent cohorts. A four-gene metabolic signature consisting of CYP4F3, PFKL, G6PD, and DNMT3A was identified as an independent predictor of overall survival. Patients in the high-risk group showed significantly poorer survival outcomes compared with low-risk patients (<i>p</i> &lt; 0.0001). The prognostic model demonstrated stable and reliable predictive performance across training, testing, and validation cohorts. Functional enrichment analyses revealed that the identified genes are closely associated with metabolic pathways, immune-related signaling, and leukemic microenvironment remodeling. Notably, increased expression of G6PD and PFKL was associated with adverse prognosis, supporting the contribution of altered glycolysis and redox homeostasis to AML pathogenesis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings establish a metabolic-based prognostic signature with strong predictive utility in AML. The identified metabolic hub genes provide insight into the interaction between metabolic dysregulation and immune remodeling in leukemia and may serve as promising biomarkers for risk stratification and potential therapeutic targets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Cervical Cancer Awareness Among Women of Reproductive Age in the Democratic Republic of the Congo: Evidence From a Nationwide DHS Analysis","authors":"Jovinary Adam,&nbsp;Olivier Mukuku,&nbsp;Stanislas Maseb’a Mwang Sulu,&nbsp;Joseph Bulanda Nsambi,&nbsp;Janvier Mwemedi Tawi,&nbsp;Alphoncina Kagaigai,&nbsp;Pankras Luoga","doi":"10.1002/cnr2.70633","DOIUrl":"10.1002/cnr2.70633","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cervical cancer (CC) is a major public health concern, ranked as the fourth leading cause of cancer. Evidence shows that CC is preventable if detected and treated at the early stages. In the Democratic Republic of the Congo (DRC), national-level evidence on women’s awareness of CC and its associated factors remains limited.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to assess the level of cervical cancer awareness and identify factors associated with awareness among women of reproductive age in the DRC.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cervical cancer (CC) is a major public health concern, ranked as the fourth leading cause of death. Evidence shows that CC is preventable if diagnosed at the early stages. In the Democratic Republic of the Congo (DRC), there is limited evidence at the national level and on factors associated with CC awareness among women of reproductive age. This study aimed to address this gap.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study analysed secondary data from a total weighted sample of 27 583 women aged 15–49, drawn from the 2023–2024 DRC Demographic and Health Survey (DRCDHS). The dependent variable was CC awareness, and the independent variables were the sociodemographic characteristics of a woman. Descriptive, bivariable and multivariable analyses were conducted. A significant factor was determined at &lt;i&gt;p&lt;/i&gt;-value &lt; 0.05 at 95% confidence intervals (CIs).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The overall CC awareness among women of reproductive age in DRC was 21.3% (95% CI = 19.5–23.2). Logistic regression results revealed that women aged 25–34 (AOR = 1.36; 95% CI = 1.12–1.66) and 35–49 (AOR = 1.60; 95% CI = 1.27–2.02), women who were residing in urban areas (AOR = 1.53; 95% CI = 1.06–2.20), women with primary education (AOR = 1.45; 95% CI = 1.03–2.04), secondary education and above (AOR = 1.73; 95% CI = 1.22–2.45), employed women (AOR = 1.48; 95% CI = 1.20–1.84), women who had been examined for breast cancer (AOR = 4.72; 95% CI = 2.91–7.67), women who had been listening to radio (AOR = 1.60; 95% CI = 1.28–1.99), women who had visited health facility last 12 months (AOR = 1.63; 95% CI = 1.35–1.97), Christian (AOR = 2.35; 95% CI = 1.06–5.21), use internet (AOR = 1.67; 95% CI = 1.23, 2.28), reading newspaper/magazine (AOR = 1.33; 95% CI = 1.01–1.76) and delivered at health facility (AOR = 1.53; 95% CI = 1.18–1.98) were statist","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil","authors":"Thais Alcantara Bonilha,&nbsp;Deborah Sutter Ayres Pereira,&nbsp;Alice Maria Boulhosa de Azevedo,&nbsp;Adriana Martins de Sousa,&nbsp;Elaine Sobral da Costa,&nbsp;Marcelo Gerardin Poirot Land","doi":"10.1002/cnr2.70640","DOIUrl":"10.1002/cnr2.70640","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute myeloid leukemia (AML) represents 15% to 20% of all pediatric acute leukemias and is responsible for nearly 30% of deaths in this population. While high-income countries report overall survival (OS) rates near 75%, survival in Brazil remains significantly lower, ranging between 30% and 40%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this study is to analyze the probability of OS and event-free survival (EFS) in pediatric patients with AML treated at a Brazilian university hospital, evaluate prognostic factors, and compare outcomes with international data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This retrospective study included 51 patients (under 14 years old) diagnosed between 2004 and 2023 and treated with BFM-based protocols. The median age was 4.6 years. Patients with acute promyelocytic leukemia (APL) achieved an OS of 100% and EFS of 90%. For other AML subtypes, the 5-year OS and EFS were 53.7% and 43.7%, respectively. Implementation of improved supportive care (ISC) after 2008—including the opening of a pediatric ICU and better infection management—was a pivotal prognostic factor (<i>p</i> &lt; 0.001). Following ISC implementation, OS increased dramatically from 8.3% to 74.5%, and the early death rate dropped to 5.7%, reaching levels comparable to high-income countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Pediatric AML outcomes in developing regions can achieve international standards when intensive chemotherapy is combined with optimized supportive care. The establishment of specialized pediatric intensive care and advanced management of infectious complications are essential pillars for bridging the survival gap in these populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13430046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.","authors":"Manuel R Espinoza-Gutarra, Brooke Jarret, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae","doi":"10.1002/cnr2.70657","DOIUrl":"10.1002/cnr2.70657","url":null,"abstract":"<p><strong>Background and aims: </strong>Acute myeloid leukemia (AML) remains the most common cause of death in adults with acute leukemia. Tyrosine kinase inhibitors (TKIs) have shown significant clinical efficacy in defined patient subgroups. Real-world outcomes of AML patients undergoing TKI therapy have not been widely reported.</p><p><strong>Methods: </strong>In this real-world retrospective study, we included 482 adult patients with AML treated with a TKI targeting FLT3, IDH1, or IDH2 from January 1, 2015, to December 31, 2023, in the countrywide Flatiron Health electronic health record-derived deidentified database. We utilized unadjusted Kaplan-Meier methods to calculate median real-world event-free survival (rwEFS) and overall survival (rwOS). We utilized a multivariable Cox regression model to evaluate characteristics associated with rwOS, modeling post-TKI stem cell transplant (SCT) as a time-varying covariate.</p><p><strong>Results: </strong>Those who received treatment at 1L (first-line) and 2L+ (second-line and beyond) had similar length of TKI therapy (3.7 vs. 3.4 months), rwEFS (2.2 vs. 2.5 months), and rwOS (12.3 vs. 13.1 months), respectively. Among all patients, greater rwOS was associated with receiving pre-TKI SCT (p < 0.001), commercial insurance (vs. Medicaid; p = 0.035), younger age (p = 0.043), and favorable 2017 ELN risk classification (vs. adverse; p = 0.032). When restricted to patients treated with TKI at 2L+ without prior SCT, rwEFS were 1.4, 1.6, and 2.1 months by targetable mutation (IDH2, IDH1, and FLT3), and rwOS were 8.7, 15.4, and 9.5 months, respectively.</p><p><strong>Conclusion: </strong>Patients treated with HMA plus TKI did not have significant differences compared to TKI alone. In this substantial, real-world cohort of AML patients receiving TKIs, clinical outcomes remained deficient irrespective of timing of TKI start, mutational target, and concurrent HMA.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":"e70657"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ANXA1/FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K/AKT-Associated PGC1α Regulation.","authors":"Zhou Li, Jiang Mingrui, Zhou Yueyang, Qi Hang, Liu Qing, Yan Xiaoyu, Yu Huimei, Xia Meihui","doi":"10.1002/cnr2.70637","DOIUrl":"10.1002/cnr2.70637","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer has the highest mortality among gynecologic malignancies, and acquired resistance to paclitaxel severely limits its clinical efficacy.</p><p><strong>Aims: </strong>This study aimed to investigate whether the ANXA1/FPR axis contributes to paclitaxel resistance in ovarian cancer and to elucidate the underlying molecular mechanisms.</p><p><strong>Methods and results: </strong>Using the ANXA1 mimetic peptide Ac2-26 and the FPR antagonist Boc2, we provided pharmacological evidence that activation of the ANXA1/FPR axis promotes paclitaxel resistance in ovarian cancer cells. Mechanistically, ANXA1/FPR signaling activated the PI3K/AKT pathway and upregulated PGC1α, leading to enhanced mitochondrial biogenesis and adaptive energy metabolism remodeling, which in turn prevented paclitaxel-induced cell death.</p><p><strong>Conclusion: </strong>Our findings suggest that the ANXA1/FPR/PI3K/AKT/PGC1α axis may represent a potential therapeutic target for overcoming paclitaxel resistance in ovarian cancer.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":"e70637"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13491153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer.","authors":"Dai Koguchi, Hideyasu Tsumura, Ken-Ichi Tabata, Takefumi Satoh, Takashi Tachibana, Shuhei Hirano, Masaomi Ikeda, Daisuke Ishii, Kazumasa Matsumoto","doi":"10.1002/cnr2.70662","DOIUrl":"10.1002/cnr2.70662","url":null,"abstract":"<p><strong>Background: </strong>Skin rash (SR) is a key issue in the long-term use of apalutamide (APA) in patients with prostate cancer (PCa); however, there is currently no established strategy for the safe management of APA in preventing SR.</p><p><strong>Aims: </strong>To investigate the predictive value of early elevation in the proportion of eosinophils (EE) for SR in patients treated with APA for PCa.</p><p><strong>Methods and results: </strong>We retrospectively reviewed the clinical data of 78 patients who received APA for PCa between April 2021 and November 2024. Early EE was defined as beyond the upper normal limit of 5.0% within 3 months of APA treatment initiation. The initial SR (I-SR) and recurrent (R-) SR incidences were compared between patients with and without early EE. During a median follow-up period of 14.7 months, 35 patients (44.9%) developed SR, and a significantly higher proportion of patients with early EE had I-SR than those without early EE (87.5% [7/8] vs. 40.0% [28/70]; p = 0.020). Six of the seven patients with early EE and I-SR had EE before the onset of I-SR (85.7%). In terms of R-SR, among patients who reduced the APA dose after I-SR, R-SR remained significantly more prevalent in patients with early EE compared with that in patients without early EE (75.0% [3/4] vs. 11.1% [2/18]; p = 0.016).</p><p><strong>Conclusion: </strong>The present study suggests that early EE has predictive value for I- and R-SR in patients who receive APA for PCa. Further large-scale studies are warranted to verify the clinical utility of early EE in patients with APA.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":"e70662"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of an Outpatient Consultation Model for Cancer-Related Fatigue by the Bavarian Cancer Society: Service Utilization and Patient Satisfaction.","authors":"K Müller, I Fischer, M Besseler, M E Heim, J U Rüffer, J Weis, T Pukrop, M Koller","doi":"10.1002/cnr2.70638","DOIUrl":"10.1002/cnr2.70638","url":null,"abstract":"<p><strong>Background: </strong>Cancer-related fatigue (CRF) is a common, debilitating consequence of cancer and its treatment, yet it remains frequently underrecognized and undertreated. As a result, many patients receive neither targeted assessment nor appropriate treatment recommendations. This study evaluates the utilization, intervention uptake, and patient satisfaction with a specialized CRF consultation service at 10 cancer counseling centers in Bavaria, Germany.</p><p><strong>Method: </strong>A prospective, observational, multicenter study was conducted between March 2022 and February 2024. Patients with a cancer diagnosis and clinically relevant fatigue were eligible for CRF consultation. Of the 557 patients who received a CRF consultation, 524 participated in the study, of whom 496 were clinically diagnosed with CRF; 447 completed the follow-up.</p><p><strong>Results: </strong>Among patients with confirmed CRF (n = 496), a shared decision-making process involving patient and clinician resulted in the selection of three evidence-based interventions in most cases (80%), most commonly physical activity (63%), energy conservation and activity management (45%), and mind-body approaches (39%). At follow-up (n = 447), 44% of the recommended interventions had been implemented either fully or to a large extent. Even for the most frequently selected interventions, implementation remained moderate (33% to 56%). Barriers to implementation-which were primarily related to health limitations, family and work commitments, and limited service availability-were reported by 87% of the patients. Despite these challenges, satisfaction with the consultation was high (mean value of 1.2 and 1.4, on a scale from 1 = very good to 6 = very poor), and patients expressed strong support for continuing the service. Suggestions for improvement included shorter waits, assistance in implementing interventions, and support with administrative procedures.</p><p><strong>Conclusion: </strong>The CRF consultation service of the Bavarian Cancer Society is a feasible, well-accepted, and patient-centered approach that addresses a major unmet need in cancer care. This model may serve as a best practice example for similar initiatives nationally and internationally. Long-term implementation in the healthcare system requires structural integration, sustainable funding, and policy recognition.</p><p><strong>Trial registration: </strong>German Clinical Trials Register: DRKS00028264.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":"e70638"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}